ResultsIQ

ResultsIQ › Latest results › Mankind Pharma Limited

Mankind Pharma Limited Q4 FY26 earnings call summary

NSE: MANKIND · BSE: 543904

Earnings call of 20 May 2026, summarised by AI from the filing.

Mankind Pharma Q4 FY26 revenue rose 11.8% to ₹3,443 cr with adjusted EBITDA margin at 27.1%; FY27 EBITDA margin guided at 25.5-26.5%.

Key takeaways

  1. Q4 revenue Revenue ₹3,443 cr, up 11.8% year-on-year, with adjusted EBITDA margin at 27.1%.
  2. FY27 guidance Management guides FY27 EBITDA margin of 25.5% to 26.5% and double-digit top line growth.
  3. Margin expansion Q4 adjusted EBITDA margin rose 400 bps year-on-year to 27.1% from 23.1%.
  4. Chronic growth Chronic share rose 120 bps year-on-year to approximately 40% in Q4, driving better sales mix.
  5. Raw material risk Disruption in raw materials, packaging material and excipients due to Middle East war issues.

Original filing on BSE

Mankind Pharma Limited Q1 FY27 results

As filed: Revenue ₹4,031 cr (+13% year on year), EBITDA ₹1,056 cr (+25% year on year), PAT ₹574 cr (+29% year on year), EBITDA margin 26.2% (+248 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹3,443 cr (+12% year on year), EBITDA ₹930 cr (+36% year on year), PAT ₹559 cr (+32% year on year), EBITDA margin 27.0% (+479 bps). Score 63 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was well above it; profit growth was above it. EBITDA margin rose 479 bps year on year. Revenue fell 3% from last quarter. Revenue rose ₹364 cr on a year ago, against ₹638 cr the year before. Share price after the results: −3.5% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹3,567 cr (+10% year on year), EBITDA ₹919 cr (+11% year on year), PAT ₹414 cr (+24% year on year), EBITDA margin 25.8% (+8 bps). Score 42 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit before exceptional items growth was above it. EBITDA margin was flat year on year. Revenue fell 4% from last quarter. Revenue rose ₹337 cr on a year ago, against ₹623 cr the year before. Share price after the results: +3.0% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹3,697 cr (+20% year on year), EBITDA ₹922 cr (+8% year on year), PAT ₹520 cr (−21% year on year), EBITDA margin 24.9% (−272 bps). Score 44 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 272 bps year on year. Revenue rose ₹620 cr on a year ago, more than the ₹369 cr it added the year before. Share price after the results: −4.5% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹3,570 cr (+23% year on year), EBITDA ₹847 cr (+24% year on year), PAT ₹445 cr (−18% year on year), EBITDA margin 23.7% (+15 bps). Score 56 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin rose 15 bps year on year. Revenue rose ₹677 cr on a year ago, more than the ₹314 cr it added the year before. Share price after the results: −3.7% in 29 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹3,079 cr (+26% year on year), EBITDA ₹684 cr (+16% year on year), PAT ₹425 cr (−11% year on year), EBITDA margin 22.2% (−200 bps). Score 40 of 100, Below trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 200 bps year on year. Other income 49% of PBT. Revenue fell 5% from last quarter. Share price after the results: −9.6% in 30 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹3,230 cr (+24% year on year), EBITDA ₹830 cr (+37% year on year), PAT ₹385 cr (−16% year on year), EBITDA margin 25.7% (+241 bps). Score 64 of 100, In line with trend. EBITDA margin rose 241 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 42% from last quarter.
  • Q2 FY25: Revenue ₹3,077 cr (+14% year on year), EBITDA ₹851 cr (+25% year on year), PAT ₹659 cr (+29% year on year), EBITDA margin 27.7% (+244 bps). Score 69 of 100, Above trend. EBITDA margin rose 244 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Mankind Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.